AR052850A1 - Indoles de utilidad en el tratamiento antiinflamatorio - Google Patents

Indoles de utilidad en el tratamiento antiinflamatorio

Info

Publication number
AR052850A1
AR052850A1 ARP050105597A ARP050105597A AR052850A1 AR 052850 A1 AR052850 A1 AR 052850A1 AR P050105597 A ARP050105597 A AR P050105597A AR P050105597 A ARP050105597 A AR P050105597A AR 052850 A1 AR052850 A1 AR 052850A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
substituents selected
group
ring
alkyl
Prior art date
Application number
ARP050105597A
Other languages
English (en)
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Publication of AR052850A1 publication Critical patent/AR052850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)

Abstract

utiles en el tratamiento de enfermedades en donde se desea y/o necesita inhibir la actividad de un miembro de la familia de MAPEG, y particularmente en el tratamiento antiinflamatorio. Producto combinado, uso de los compuestos, proceso para obtenerlos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde uno de los grupos R2, R3, R4 y R5 representa -D-E y: a) los otros grupos se seleccionan en forma independiente entre hidrogeno, G1, un grupo arilo, un grupo heteroarilo (estando dichos ultimos dos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre A), alquil C1-8 y un grupo heterocicloalquilo (estando dichos ultimos dos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; y/o b) todos los otros pared de dos grupos que se encuentran adyacentes entre sí están opcionalmente ligados para formar, junto con dos átomos del anillo de benceno esencial en el compuesto de la formula (1), un anillo de 3 a 8 miembros, que contiene opcionalmente entre 1 y 3 heteroátomos, estando el anillo propiamente dicho opcionalmente sustituido por uno o más sustituyentes seleccionados entre halo, -R6, -OR6 y =O; D representa un enlace simple, -O-, -C(R7)(R8)-, alquileno C2-4, -C(O)- o -S(O)m-; R1 y E representan en forma independiente un grupo arilo o un grupo heteroarilo, estando ambos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre A; R7 y R8 representan en forma independiente H, halo o alquilo C1-6, estando dicho ultimo grupo opcionalmente sustituido por halo, o R7 y R8 pueden formar juntos, con el átomo de carbono al cual están unidos, un anillo de 3 a 6 miembros, donde dicho anillo contiene opcionalmente un heteroátomo y está opcionalmente sustituido por uno o más sustituyentes seleccionados entre halo y alquilo C1-3, estando dicho ultimo grupo opcionalmente sustituido por uno o más sustituyente halo; Q representa un enlace simple, o una cadena alquileno C1-8 o heteroalquileno C2-8, donde ambos de los dos ultimos grupos contienen opcionalmente una o más instauraciones y están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; X1 representa: a) -C(O)OR9a, -C(O)N(R10b)R9b, -C(O)N(H)C(=NR9c)N(R10d)R9d; -C(O)N(H)CN, -S(O)3R9e, -P(O)(OR9f)2, -P(O)(OR9g)N(R10h)R9h, -P(O)(N(R10i)R9i)2, -B(OR9y)2, -C(O)N(H)S(O)2R11 o, con la salvedad de que T no represente un enlace simple cuando Y representa -C(O)OR9a, tetrazolilo no sustituido; b) un grupo arilo o un grupo heteroarilo, ambos sustituidos por al menos un sustituyente seleccionado entre X2, y uno o más sustituyentes opcionales seleccionados entre A; o c) un grupo heterocicloalquilo sustituido por al menos un sustituyente seleccionado entre X2, y uno o más sustituyentes opcionales seleccionados entre G1 y/o Z1; X2 representa -C(O)OR9a, -C(O)N(R10b)R9b, -C(O)N(H)C(=NR9c)N(R10d)R9d; -C(O)N(H)CN, -S(O)3R9e, - P(O)(OR9f)2, -P(O)(OR9g)N(R10h)R9h, -P(O)(N(R10i)R9i)2, -B(OR9y)2, -C(O)N(H)S(O)2R11 o tetrazolilo insustituido; T representa: a) un enlace simple; b) una cadena alquileno C1-8 o heteroalquileno, y estos dos ultimos grupos: i) contienen opcionalmente una o más insaturaciones; ii) están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; y/o iii) pueden comprender un anillo adicional de 3 a 8 miembros formado entre uno o más miembros cualquiera de la cadena C1-8 alquileno o heteroalquileno C2-8, donde dicho anillo contiene opcionalmente entre 1 y 3 heteroátomos y/o entre 1 y 3 insaturaciones y estando el anillo propiamente dicho opcionalmente sustituido por uno o más sustituyentes seleccionados entre G1 y/o Z1; c) un grupo arileno o grupo heteroarileno, estando ambos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre A; o d) -T1-W1-T2-; uno de T1 y T2 representa una cadena alquileno C1-8 o heteroalquileno C2- 8, y estos dos ultimos grupos: i) contienen opcionalmente una o más instauraciones; ii) están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; y/o iii) pueden comprender un anillo adicional de 3 a 8 miembros formado entre uno o más miembros cualquiera de la cadena alquileno C1-8 o heteroalquileno C2-8, donde dicho anillo contiene opcionalmente entre 1 y 3 heteroátomos y/o entre 1 y 3 insaturaciones y estando el anillo propiamente dicho opcionalmente sustituido por uno o más sustituyentes seleccionados entre G1 y/o Z1; y el otro representa un grupo arileno o un grupo heteroarileno, estando ambos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre A; W1 representa -O- o -S(O)m-; m representa 0, 1 o 2; Y representa C(H)(CF3)OH, -C(O)CF3, -C(OH)2CF3, -C(O)OR9a, -S(O)3R9e, -P(O)(OR9f)2, -P(O)(OR9g)N(R10h)R9h, -P(O)(N(R10i)R9i)2, -B(OR9y)2, -C(CF3)2OH, -S(O)2N(R10z)R9z o cualquiera de los grupos de formulas (2), R6, R9a a R9z, R10b, R10d, R10h; R10i, R10j y R10z representa en forma independiente: I) hidrogeno; II) un grupo arilo o un grupo heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre B; o III) alquilo C1-8 o un grupo heterocicloalquilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; o cualquier par de R9a a R9y y R10b, R10d, R10h, R10i o R10j, pueden unirse para formar, junto con el/los átomos de carbono a los cuales están unidos, un anillo de 3 a 8 miembros, que contiene opcionalmente entre 1 y 3 heteroátomos y/o entre 1 y 3 enlaces dobles, estando dicho anillo opcionalmente sustituido por uno o más sustituyentes seleccionados entre G1y/o Z1; R11 I) un grupo arilo o un grupo heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre B; o II) alquilo C1-8 o un grupo heterocicloalquilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; A representa: I) un grupo arilo o un grupo heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre B; II) alquilo C1-8 o un grupo heterocicloalquilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G1 y/o Z1; o II) un grupo G1; G1 representa halo, ciano, -N3, -NO2, -ONO2- o -A1-R12a; en donde A1 representa un enlace simple o un grupo espaciador seleccionado entre (O)A2-, -S(O)2A3-, -N(R13a)A4-, o -OA5-, en el cual: A2 representa un enlace simple, -O-, -N(R13b)- o -C(O)-; A3 representa un enlace simple, -O- o -N(R13c)-; A4 y A5 representan en forma independiente un enlace simple, -C(O)-, -C(O)N(R13d)-, -C(O)O-, -S(O)2- o -S(O)2N(R13e)-; Z1 representa =O, =S, =N0R12b, =NS(O)2N(R13f)R12c, =NCN o =C(H)NO2; B representa: I) un grupo arilo o un grupo heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G2, II) alquilo C1-8 o un grupo heterocicloalquilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G2 y/o Z2; o III) un grupo G2; G2; representa halo, ciano, -N3, -NO2, -ONO2 o -A6-R14a; en donde A6 representa un enlace simple o un grupo espaciador seleccionado entre -C(O)A7-, -S(O)2A8-, -N(R15a)A9- o -OA10-, en el cual: A7 representa un enlace simple, -O-, -N(R15b)- o -C(O)-; A8 representa un enlace simple, -O- o -N(R15c)-; A9 y A10 representa en forma independiente un enlace simple, -C(O)-, -C(O)N(R15d)-, -C(O)O-, -S(O)2- o -S(O)2N(R15e)-; Z2 representa =O, =S, -NOR14b, =NS(O)2N(R15f)R14c, =NCN o =C(H)NO2; R12a, R12b, R12c, R13a, R13b, R13c, R13d, R13e, R13f, RI4a, R14b, R14c, R15a, R15b, R15c, R15d, R15e y R15f se seleccionan en forma independiente entre: i) hidrogeno; ii) un grupo arilo o un grupo heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre G3; iii) alquilo C1-8 o un grupo heterocicloalquilo, ambos de los cuales están opcionalmente sustituidos por G3 y/o Z3; o cualquier par de R12a a R12c y R13a a R13f, y/o R14a a R14c y R15a a R15f, pueden unirse para formar con dichos átomos de carbono u otros revelantes un anillo adicional de 3 a 8 miembros, que contiene opcionalmente entre 1 y 3 heteroátomo y/o entre 1 y 3 enlaces dobles, estando dicho anillo opcionalmente sustituido por uno o más sustituyentes seleccionados entre G3 y/o Z3; G3 representa halo, ciano, -N3, -NO2, -ONO2 o -A11-R16a; en donde A11 representa un enlace simple o un grupo espaciador seleccionado entre -C(O)A12-, -S(O)2A13-, -N(R17a)A14- o -OA15-, en el cual: A12 representa un enlace simple, -O-, -N(17b)- o -C(O)-; A13 representa un enlace simple, -O- o -N(R17c)-; A14 y A15 representan independientemente en forma independiente un enlace simple, -C(O)-, -C(O)N(R17d)-, -C(O)O-, -S(O)2- o - S(O)2N(R17e)-; Z3 representa =O, =S, =NOR16b, =NS(O)2N(R17f)R16c, =NCN o =C(H)NO2; R16a, R16b, R16c, R17a, R17b, R17c, R17d, R17e y R17f se seleccionan en forma independiente entre: i) hidrogeno; ii) alquilo C1-6 o un grupo heterocicloalquilo, estando ambos grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados entre halo, alquilo C1-4, -N(R18a)R19a, -OR18b y =O; y iii) un grupo arilo o heteroarilo, ambos de los cuales están opcionalmente sustituidos por uno o más sustituyentes seleccionados entre halo, alquilo C1-4, -N(R18c)R19b y -OR18d; o cualquier par de R16a a R16c y R17a a R17f pueden unirse para formar con dichos átomos de carbono u otros relevantes un anillo adicional de 3 a 8 miembros, que contiene opcionalmente entre 1 y 3 heteroátomos y/o entre 1 y 3 enlaces dobles, estando dicho anillo opcionalmente sustituido por uno o más sustituyentes seleccionados entre halo, alquilo C1-4, -N (R18e)R19c, -OR18f y =O; R18a, R18b, R18c, R18d, R18e, R18f, R19a, R19b y R19c se seleccionan en forma independiente entre hidrogeno y alquilo C1-4, estando dicho ultimo grupo opcionalmente
ARP050105597A 2005-01-19 2005-12-28 Indoles de utilidad en el tratamiento antiinflamatorio AR052850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64455805P 2005-01-19 2005-01-19

Publications (1)

Publication Number Publication Date
AR052850A1 true AR052850A1 (es) 2007-04-04

Family

ID=34956618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105597A AR052850A1 (es) 2005-01-19 2005-12-28 Indoles de utilidad en el tratamiento antiinflamatorio

Country Status (19)

Country Link
US (1) US8097623B2 (es)
EP (1) EP1841735B1 (es)
JP (1) JP2008527029A (es)
KR (1) KR20070114123A (es)
CN (1) CN101142185A (es)
AR (1) AR052850A1 (es)
AT (1) ATE501119T1 (es)
AU (1) AU2005325497A1 (es)
BR (1) BRPI0519774A2 (es)
CA (1) CA2593155A1 (es)
DE (1) DE602005026867D1 (es)
EA (1) EA200701504A1 (es)
HK (1) HK1105975A1 (es)
IL (1) IL184356A0 (es)
MX (1) MX2007008759A (es)
NO (1) NO20073416L (es)
TW (1) TW200637819A (es)
WO (1) WO2006077366A1 (es)
ZA (1) ZA200705827B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765775B1 (en) * 2004-06-18 2009-04-29 Biolipox AB Indoles useful in the treatment of inflammation
US20100197687A1 (en) * 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
US8293781B2 (en) 2007-03-29 2012-10-23 Daiichi Sankyo Company, Limited Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2010076566A2 (en) 2008-12-30 2010-07-08 Biolipox Ab Indoles useful in the treatment of inflammation
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010103278A1 (en) 2009-03-12 2010-09-16 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
EP2429994A1 (en) 2009-03-12 2012-03-21 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
EP2406223A2 (en) 2009-03-12 2012-01-18 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
US20120004228A1 (en) 2009-03-12 2012-01-05 Biolipox Ab Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
WO2011110824A1 (en) 2010-03-12 2011-09-15 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
JP2012211085A (ja) * 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
GB201006846D0 (en) 2010-04-23 2010-06-09 Glaxo Group Ltd Novel compounds
US9212139B2 (en) 2010-06-16 2015-12-15 Purdue Pharma, L.P. Aryl substituted indoles and their use as blockers of sodium channels
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014100158A1 (en) 2012-12-18 2014-06-26 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
KR101497979B1 (ko) * 2013-02-04 2015-03-03 서울대학교산학협력단 인돌 유도체 및 이를 포함하는 ｒａｇｅ 관련 질환의 예방 또는 치료용 약학적 조성물
AU2014248717B2 (en) 2013-03-12 2018-03-29 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
AU2015374118B2 (en) 2014-12-29 2020-07-23 The Trustees Of The University Of Pennsylvania Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
CN105085401B (zh) * 2015-08-17 2018-02-13 北京大学 六氢吲唑类15‑脂氧合酶激活剂及应用
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
TWI751271B (zh) 2017-01-23 2022-01-01 美商凱登製藥公司 鉀離子通道調節子
US11690824B2 (en) 2018-04-10 2023-07-04 The General Hospital Corporation Antibacterial compounds
CN108586432B (zh) * 2018-05-31 2020-08-25 温州医科大学 一种3-(吲哚-5-基)-吲唑衍生物及其应用
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
CN111285846B (zh) * 2018-12-06 2021-08-06 中国科学院大连化学物理研究所 一种2-(2-吲哚基)-乙酸酯衍生物及其合成方法
CN112301370B (zh) * 2020-10-12 2022-04-22 湖南科技学院 一种1,3-二甲基-3-二氟乙基-2-氧化吲哚化合物的电化学合成方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1241660A (en) 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
LU85435A1 (fr) 1984-06-27 1986-01-24 Amylum Graanderivaten Raff Procede de preparation d'un carboxymethylamidon,carboxymethylamidon ainsi obtenu et produit de lavage contenant un tel carboxymethylamidon
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
JPS62138469A (ja) * 1985-12-11 1987-06-22 Yoshitomi Pharmaceut Ind Ltd インド−ル誘導体
NZ222878A (en) 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
US5374615A (en) * 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
ATE197051T1 (de) 1992-04-03 2000-11-15 Upjohn Co Pharmazeutisch wirksame bicyclisch heterocyclische amine
US5294722A (en) * 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5236916A (en) * 1992-05-26 1993-08-17 E. R. Squibb & Sons, Inc. Oxadiazinone substituted indole and benzimidazole derivatives
TW229140B (es) 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
RU2152385C1 (ru) 1994-07-27 2000-07-10 Санкио Компани Лимитед Гетероциклические соединения, применимые в качестве аллостерических эффекторов при мускариновых рецепторах
AU4514496A (en) 1994-12-13 1996-07-03 Smithkline Beecham Corporation Novel compounds
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
US5910622A (en) 1996-10-29 1999-06-08 Dcv, Inc. Method for treating fibrous cellulosic materials
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE19742263A1 (de) 1997-09-25 1999-04-01 Asta Medica Ag Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva
BR9814340B1 (pt) 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
GB9803228D0 (en) * 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EA200000868A1 (ru) * 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипаз
US6828344B1 (en) * 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU765427B2 (en) 1998-02-25 2003-09-18 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
CA2322163A1 (en) * 1998-02-25 1999-09-02 John Mckew Inhibitors of phospholipase a2
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6277878B1 (en) 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
IT1303260B1 (it) 1998-10-28 2000-11-06 Chemi Spa Procedimento per preparare composti indolici.
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AU5780800A (en) 1999-06-29 2001-01-31 Uab Research Foundation, The Methods of treating fungal infections with inhibitors of nad synthetase enzyme
JP2001069477A (ja) * 1999-08-31 2001-03-16 Sony Corp 番組提供システム及び番組提供方法
EP1284728A4 (en) 1999-10-22 2004-05-19 Merck & Co Inc MEDICINES FOR TREATING ADDICTIC ADDICTION
WO2001032621A1 (fr) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
US6353007B1 (en) 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
JP2004529855A (ja) * 2000-10-10 2004-09-30 スミスクライン ビーチャム コーポレーション 置換インドール類、そのような置換インドール類を含む医薬組成物及びＰＰＡＲ−γ結合剤としてのそれらの使用
CA2461360A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
KR20040047862A (ko) 2001-09-27 2004-06-05 에프. 호프만-라 로슈 아게 Ｃｏｘ ⅱ 억제제로서의 인돌 유도체
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7148250B2 (en) 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
US7186746B2 (en) * 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2497868C (en) 2002-09-06 2010-11-30 Janssen Pharmaceutica, N.V. Heterocyclic compounds
EP1579010A4 (en) * 2002-10-17 2010-07-21 Decode Genetics Ehf SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
CA2528626A1 (en) 2003-07-09 2005-01-20 Biolipox Ab Indoles useful in the treatment of inflammation
EP1778633B1 (en) * 2004-06-18 2008-12-03 Biolipox AB Indoles useful in the treatment of inflammation
EP1765775B1 (en) * 2004-06-18 2009-04-29 Biolipox AB Indoles useful in the treatment of inflammation
KR20070028553A (ko) * 2004-06-18 2007-03-12 바이올리폭스 에이비 염증 치료에 유용한 인돌
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
WO2006077364A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1841766A1 (en) 2005-01-19 2007-10-10 Biolipox AB Pyrrolopyridines useful in the treatment of inflammation
US20100197687A1 (en) 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
JP2008527028A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類

Also Published As

Publication number Publication date
IL184356A0 (en) 2007-10-31
NO20073416L (no) 2007-10-05
EP1841735B1 (en) 2011-03-09
CN101142185A (zh) 2008-03-12
TW200637819A (en) 2006-11-01
KR20070114123A (ko) 2007-11-29
MX2007008759A (es) 2007-09-11
ZA200705827B (en) 2008-10-29
US20090076004A1 (en) 2009-03-19
US8097623B2 (en) 2012-01-17
AU2005325497A1 (en) 2006-07-27
DE602005026867D1 (de) 2011-04-21
EA200701504A1 (ru) 2008-02-28
WO2006077366A1 (en) 2006-07-27
BRPI0519774A2 (pt) 2009-02-10
EP1841735A1 (en) 2007-10-10
HK1105975A1 (en) 2008-02-29
CA2593155A1 (en) 2006-07-27
JP2008527029A (ja) 2008-07-24
ATE501119T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
AR052850A1 (es) Indoles de utilidad en el tratamiento antiinflamatorio
AR053111A1 (es) Indoles de utilidad en el tratmiento antiinflamatorio
AR053993A1 (es) Indoles de utilidad en el tratamiento antiinflamatorio
RU2017109664A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
AU2007276621B2 (en) Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
JP2019529490A5 (es)
AR084217A1 (es) Inhibidores macrociclicos de virus flaviviridae
JP2013521312A5 (es)
RU2011112393A (ru) 8-замещенные производные изохинолина и их применение
JP2009538276A5 (es)
CO5261616A1 (es) Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
EA200700432A1 (ru) Галогенированные производные бензамида
RU2009136445A (ru) Способ получения высокочистого празугрель гидрохлорида
US20090186859A1 (en) Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods
Nowak et al. Discovery and initial optimization of 5, 5′-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors
CY1109491T1 (el) Συζυγη μακρολιδων με αντιφλεγμονωδη δραση
JP2008500361A5 (es)
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
NI200400073A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
ECSP024383A (es) Derivados de nitrilo beta-aminoacidos
CA2710791A1 (en) Pyripyropene derivatives having an acat2-inhibiting activity
JP2006523698A5 (es)
DE60120427D1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
CA2353402A1 (en) 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
RU2012138410A (ru) Соединение, содержащее кольцо пиридина, и способ получения галогенированного производного пиколина и производного тетразолилоксима

Legal Events

Date Code Title Description
FB Suspension of granting procedure